Table 2 Demographics and baseline clinical characteristics of the RA patients
Baseline characteristics | Overall n = 625 | Responder n = 466 | Non-responder n = 159 | p-value |
|---|---|---|---|---|
Sex (male, %) | 103 (16.5) | 80 (17.2) | 23 (14.5) | 0.503 |
Age at baseline (years) | 54.04 (12.44) | 54.13 (12.40) | 53.78 (12.61) | 0.757 |
Disease duration (years) | 6.78 (7.19) | 6.66 (7.20) | 7.14 (7.17) | 0.464 |
Height (cm) | 159.41 (7.01) | 159.50 (7.08) | 159.16 (6.81) | 0.606 |
Weight (kg) | 57.30 (9.72) | 57.08 (9.45) | 57.93 (10.47) | 0.341 |
SJC | 6.71 (5.18) | 7.00 (5.10) | 5.87 (5.36) | 0.017 |
TJC | 8.50 (5.98) | 8.78 (5.98) | 7.68 (5.93) | 0.045 |
PtGA | 7.24 (1.78) | 7.47 (1.69) | 6.55 (1.87) | <0.001 |
PhGA | 6.56 (1.75) | 6.69 (1.72) | 6.18 (1.78) | 0.001 |
RAPID3 | 15.54 (5.68) | 16.10 (5.70) | 13.89 (5.30) | <0.001 |
ESR (mm/h) | 46.63 (25.66) | 46.38 (25.98) | 47.36 (24.77) | 0.678 |
CRP (mg/dL) | 2.34 (3.16) | 2.40 (3.00) | 2.16 (3.59) | 0.405 |
HTN (%) | 167 (26.7) | 126 (27.0) | 41 (25.8) | 0.838 |
DM (%) | 61 (9.8) | 36 (7.7) | 25 (15.7) | 0.005 |
CKD (%) | 5 (0.8) | 3 (0.6) | 2 (1.3) | 0.814 |
Rheumatoid factor positive (%) | 551 (88.2) | 410 (88.0) | 141 (88.7) | 0.926 |
Anti-CCP positive (%) | 494 (79.0) | 373 (80.0) | 121 (76.1) | 0.346 |
Methotrexate (%) | 531 (85.0) | 400 (85.8) | 131 (82.4) | 0.357 |
Hydroxychloroquine (%) | 175 (28.0) | 136 (29.2) | 39 (24.5) | 0.304 |
Sulfasalazine (%) | 85 (13.6) | 67 (14.4) | 18 (11.3) | 0.403 |
Leflunomide (%) | 179 (28.6) | 127 (27.3) | 52 (32.7) | 0.226 |
Abatacept (%) | 68 (10.9) | 49 (10.5) | 19 (11.9) | 0.723 |
Adalimumab (%) | 168 (26.9) | 121 (26.0) | 47 (29.6) | 0.436 |
Etanercept (%) | 94 (15.0) | 64 (13.7) | 30 (18.9) | 0.151 |
Golimumab (%) | 26 (4.2) | 18 (3.9) | 8 (5.0) | 0.684 |
Infliximab (%) | 64 (10.2) | 40 (8.6) | 24 (15.1) | 0.029 |
Tocilizumab (%) | 194 (31.0) | 165 (35.4) | 29 (18.2) | <0.001 |
Tofacitinib (%) | 11 (1.8) | 9 (1.9) | 2 (1.3) | 0.835 |